JPWO2021067100A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021067100A5 JPWO2021067100A5 JP2022520294A JP2022520294A JPWO2021067100A5 JP WO2021067100 A5 JPWO2021067100 A5 JP WO2021067100A5 JP 2022520294 A JP2022520294 A JP 2022520294A JP 2022520294 A JP2022520294 A JP 2022520294A JP WO2021067100 A5 JPWO2021067100 A5 JP WO2021067100A5
- Authority
- JP
- Japan
- Prior art keywords
- elegans
- genus
- composition
- bacterial strain
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Description
本発明の実施形態を以下の項にさらに記載する：
［項１］
（ａ）少なくとも１つの細菌株またはその抽出物もしくはその成分であって、前記少なくとも１つの細菌株が、Ｇｌｕｃｏｎｏｂａｃｔｅｒ属、Ａｃｅｔｏｂａｃｔｅｒ属、Ｇｌｕｃｏｎｏａｃａｅｔｏｂａｃｔｅｒ属、Ａｃｉｄｏｍｏｎａｓ属、Ａｍｅｙａｍａｅａ属、Ａｓａｉａ属、Ｇｒａｎｕｌｉｂａｃｔｅｒ属、Ｋｏｚａｋｉａ属、Ｎｅｏａｓａｉａ属、Ｎｅｏｋｏｍａｇａｔａｅａ属、Ｓａｃｃｈａｒｉｂａｃｔｅｒ属、Ｓｗａｍｉｎａｔｈａｎｉａ属、Ｔａｎｔｉｃｈａｒｏｅｎｉａ属、またはそれらの組み合わせを含む、前記少なくとも１つの細菌株またはその抽出物もしくはその成分と、
（ｂ）賦形剤と、を含む、組成物。
［項２］
前記少なくとも１つの細菌株が、Ｇｌｕｃｏｎａｃｅｔｏｂａｃｔｅｒ ｈａｎｓｅｎｉｉ、Ｇｌｕｃｏｎｏｂａｃｔｅｒ ｏｘｙｄａｎｓ、Ａｃｅｔｏｂａｃｔｅｒ ａｃｅｔｉ、またはそれらの組み合わせを含む、上記項１に記載の組成物。
［項３］
前記少なくとも１つの細菌株が、Ｇｌｕｃｏｎａｃｅｔｏｂａｃｔｅｒ ｈａｎｓｅｎｉｉを含む、上記項１または２に記載の組成物。
［項４］
前記少なくとも１つの細菌株またはその抽出物もしくはその成分が、Ｃ．ｅｌｅｇａｎｓ動物を含むＣ．ｅｌｅｇａｎｓ培養物に投与されるとき、前記Ｃ．ｅｌｅｇａｎｓ培養物中の前記Ｃ．ｅｌｅｇａｎｓ動物の平均寿命は、前記少なくとも１つの細菌株またはその抽出物もしくはその成分の投与なしで、同等のＣ．ｅｌｅｇａｎｓ培養物中のＣ．ｅｌｅｇａｎｓ動物のものと比較して、少なくとも２０％延長されるという点を特徴とする、上記項１～３のいずれか１項に記載の組成物。
［項５］
前記少なくとも１つの細菌株またはその抽出物もしくはその成分が、Ｃ．ｅｌｅｇａｎｓ動物を含むＣ．ｅｌｅｇａｎｓ培養物に投与されるとき、前記Ｃ．ｅｌｅｇａｎｓ培養物中の前記Ｃ．ｅｌｅｇａｎｓ動物の平均咽頭ポンピング活性は、前記少なくとも１つの細菌株またはその抽出物もしくはその成分の投与なしで、同等のＣ．ｅｌｅｇａｎｓ培養物中のＣ．ｅｌｅｇａｎｓ動物のものと比較して、少なくとも２０％増加するという点を特徴とする、上記項１～４のいずれか１項に記載の組成物。
［項６］
前記少なくとも１つの細菌株またはその抽出物もしくはその成分が、Ｃ．ｅｌｅｇａｎｓ動物を含むＣ．ｅｌｅｇａｎｓ培養物に投与されるとき、前記Ｃ．ｅｌｅｇａｎｓ培養物中の前記Ｃ．ｅｌｅｇａｎｓ動物の平均運動速度は、前記少なくとも１つの細菌株またはその抽出物もしくはその成分の投与なしで、同等のＣ．ｅｌｅｇａｎｓ培養物中のＣ．ｅｌｅｇａｎｓ動物のものと比較して、少なくとも２０％増加するという点を特徴とする、上記項１～５のいずれか１項に記載の組成物。
［項７］
前記少なくとも１つの細菌株またはその抽出物もしくはその成分が、Ｃ．ｅｌｅｇａｎｓ動物を含むＣ．ｅｌｅｇａｎｓ培養物に投与されるとき、前記Ｃ．ｅｌｅｇａｎｓ培養物中の前記Ｃ．ｅｌｅｇａｎｓ動物の生殖能力は、前記少なくとも１つの細菌株またはその抽出物もしくはその成分の投与なしで、同等のＣ．ｅｌｅｇａｎｓ培養物中のＣ．ｅｌｅｇａｎｓ動物のものと比較して、少なくとも２０％低下するという点を特徴とする、上記項１～６のいずれか１項に記載の組成物。
［項８］
前記少なくとも１つの細菌株またはその抽出物もしくはその成分が、Ｃ．ｅｌｅｇａｎｓ動物を含むＣ．ｅｌｅｇａｎｓ培養物が紫外線照射にさらされるとき、前記少なくとも１つの細菌株またはその抽出物もしくはその成分が投与された前記Ｃ．ｅｌｅｇａｎｓ培養物中の前記Ｃ．ｅｌｅｇａｎｓ動物の平均生存時間が、前記少なくとも１つの細菌株またはその抽出物もしくはその成分の投与なしで、同等のＣ．ｅｌｅｇａｎｓ培養物中のＣ．ｅｌｅｇａｎｓ動物のものと比較して、少なくとも２０％増加するという点を特徴とする、上記項１～７のいずれか１項に記載の組成物。
［項９］
前記少なくとも１つの細菌株またはその抽出物もしくはその成分が、Ｃ．ｅｌｅｇａｎｓ動物を含むＣ．ｅｌｅｇａｎｓ培養物が高温にさらされるとき、前記少なくとも１つの細菌株またはその抽出物もしくはその成分が投与された前記Ｃ．ｅｌｅｇａｎｓ培養物中のＣ．ｅｌｅｇａｎｓ動物の平均生存時間が、前記少なくとも１つの細菌株またはその抽出物もしくはその成分の投与なしで、同等のＣ．ｅｌｅｇａｎｓ培養物中のＣ．ｅｌｅｇａｎｓ動物のものと比較して、少なくとも２０％増加するという点を特徴とする、上記項１～８のいずれか１項に記載の組成物。
［項１０］
前記高温が、少なくとも３７℃である、上記項９に記載の組成物。
［項１１］
前記少なくとも１つの細菌株またはその抽出物もしくはその成分が、Ｃ．ｅｌｅｇａｎｓ動物を含むＣ．ｅｌｅｇａｎｓ培養物に投与されるとき、前記Ｃ．ｅｌｅｇａｎｓ培養物中の前記Ｃ．ｅｌｅｇａｎ動物において観察される腸脂肪の平均量が、前記少なくとも１つの細菌株またはその抽出物もしくはその成分の投与なしで、同等のＣ．ｅｌｅｇａｎｓ培養物中のＣ．ｅｌｅｇａｎｓ動物のものと比較して、少なくとも２０％低下するという点を特徴とする、上記項１～１０のいずれか１項に記載の組成物。
［項１２］
前記Ｃ．ｅｌｅｇａｎｓ動物が、成体Ｃ．ｅｌｅｇａｎｓ動物である、上記項４～１１のいずれか１項に記載の組成物。
［項１３］
前記Ｃ．ｅｌｅｇａｎｓ動物が、少なくとも５日齢である、上記項４～１２のいずれか１項に記載の組成物。
［項１４］
前記組成物が、経口投与用に配合される、上記項１～１３のいずれか１項に記載の組成物。
［項１５］
前記組成物が、食品、飲料、飼料組成物、または栄養補助食品である、上記項１～１４のいずれか１項に記載の組成物。
［項１６］
前記組成物が、液体、シロップ、錠剤、トローチ、グミ、カプセル、粉末、ゲル、またはフィルムである、上記項１～１５のいずれか１項に記載の組成物。
［項１７］
前記組成物が、医薬組成物である、上記項１～１６のいずれか１項に記載の組成物。
［項１８］
前記組成物が、腸溶コーティングされた製剤である、上記項１～１７のいずれか１項に記載の組成物。
［項１９］
対象に、上記項１～１８のいずれか１項に記載の組成物を投与することを含む、方法。
［項２０］
前記方法が、対象の寿命を延長する方法である、上記項１９に記載の方法。
［項２１］
前記対象の前記寿命が、前記組成物の投与なしで、同等の対象のものと比較して、少なくとも２０％延長される、上記項２０に記載の方法。
［項２２］
前記方法が、対象の少なくとも１つの年齢関連の症状または状態の発症を低減または遅延させる方法である、上記項１９に記載の方法。
［項２３］
前記少なくとも１つの年齢関連の症状または状態が、前記組成物の投与なしで、同等の対象のものと比較して、前記対象において少なくとも２０％低減または遅延される、上記項２２に記載の方法。
［項２４］
前記少なくとも１つの年齢関連の症状または状態が、前記対象の筋肉及び／または神経筋機能の低下であるか、またはそれを含む、上記項２２または２３に記載の方法。
［項２５］
前記少なくとも１つの年齢関連の症状または状態が、脂質代謝の調節不全であるか、またはそれを含む、上記項２２～２４のいずれか１項に記載の方法。
［項２６］
前記対象が、少なくとも３０歳である、上記項１９～２５のいずれか１項に記載の方法。
［項２７］
前記対象が、高齢対象である、上記項１９～２６のいずれか１項に記載の方法。
［項２８］
前記対象が、哺乳動物である、上記項１９～２７のいずれか１項に記載の方法。
［項２９］
前記対象が、ヒトである、上記項１９～２８のいずれか１項に記載の方法。
［項３０］
前記対象の微生物叢にコロニーを形成するのに十分な量の微生物を投与することを含む、上記項１９～２９のいずれか１項に記載の方法。
［項３１］
対象の寿命を延長するための少なくとも１つの細菌株またはその抽出物もしくはその成分の使用であって、少なくとも１つの細菌株が、Ｇｌｕｃｏｎｏｂａｃｔｅｒ属、Ａｃｅｔｏｂａｃｔｅｒ属、Ｇｌｕｃｏｎｏａｃａｅｔｏｂａｃｔｅｒ属、Ａｃｉｄｏｍｏｎａｓ属、Ａｍｅｙａｍａｅａ属、Ａｓａｉａ属、Ｇｒａｎｕｌｉｂａｃｔｅｒ属、Ｋｏｚａｋｉａ属、Ｎｅｏａｓａｉａ属、Ｎｅｏｋｏｍａｇａｔａｅａ属、Ｓａｃｃｈａｒｉｂａｃｔｅｒ属、Ｓｗａｍｉｎａｔｈａｎｉａ属、Ｔａｎｔｉｃｈａｒｏｅｎｉａ属、またはそれらの組み合わせを含む、前記使用。
［項３２］
前記少なくとも１つの細菌株が、Ｇｌｕｃｏｎａｃｅｔｏｂａｃｔｅｒ ｈａｎｓｅｎｉｉ、Ｇｌｕｃｏｎｏｂａｃｔｅｒ ｏｘｙｄａｎｓ、Ａｃｅｔｏｂａｃｔｅｒ ａｃｅｔｉ、またはそれらの組み合わせを含む、上記項３１に記載の使用。
［項３３］
前記少なくとも１つの細菌株が、Ｇｌｕｃｏｎａｃｅｔｏｂａｃｔｅｒ ｈａｎｓｅｎｉｉを含む、上記項３１または３２に記載の使用。
［項３４］
対象における少なくとも１つの年齢関連の症状もしくは状態の発症を低減または遅延させる少なくとも１つの細菌株またはその抽出物もしくは成分の使用であって、前記少なくとも１つの細菌株が、Ｇｌｕｃｏｎｏｂａｃｔｅｒ属、Ａｃｅｔｏｂａｃｔｅｒ属、Ｇｌｕｃｏｎｏａｃａｅｔｏｂａｃｔｅｒ属、Ａｃｉｄｏｍｏｎａｓ属、Ａｍｅｙａｍａｅａ属、Ａｓａｉａ属、Ｇｒａｎｕｌｉｂａｃｔｅｒ属、Ｋｏｚａｋｉａ属、Ｎｅｏａｓａｉａ属、Ｎｅｏｋｏｍａｇａｔａｅａ属、Ｓａｃｃｈａｒｉｂａｃｔｅｒ属、Ｓｗａｍｉｎａｔｈａｎｉａ属、Ｔａｎｔｉｃｈａｒｏｅｎｉａ属、またはそれらの組み合わせを含む、前記使用。
［項３５］
前記少なくとも１つの細菌株が、Ｇｌｕｃｏｎａｃｅｔｏｂａｃｔｅｒ ｈａｎｓｅｎｉｉ、Ｇｌｕｃｏｎｏｂａｃｔｅｒ ｏｘｙｄａｎｓ、Ａｃｅｔｏｂａｃｔｅｒ ａｃｅｔｉ、またはそれらの組み合わせを含む、上記項３４に記載の使用。
［項３６］
前記少なくとも１つの細菌株が、Ｇｌｕｃｏｎａｃｅｔｏｂａｃｔｅｒ ｈａｎｓｅｎｉｉを含む、上記項３４または３５に記載の使用。
［項３７］
前記少なくとも１つの年齢関連の症状または状態が、組成物の投与なしで、同等の対象のものと比較して、前記対象において少なくとも２０％低減または遅延される、上記項３４に記載の使用。
［項３８］
前記少なくとも１つの年齢関連の症状または状態が、前記対象の筋肉及び／または神経筋機能の低下であるか、またはそれを含む、上記項３４～３７のいずれか１項に記載の使用。
［項３９］
前記少なくとも１つの年齢関連の症状または状態が、脂質代謝の調節不全であるか、またはそれを含む、上記項３４～３８のいずれか１項に記載の使用。
［項４０］
前記対象が、少なくとも３０歳である、上記項３４～３９のいずれか１項に記載の使用。
［項４１］
前記対象が、高齢対象である、上記項３４～４０のいずれか１項に記載の使用。
［項４２］
前記対象が、哺乳動物である、上記項３４～４１のいずれか１項に記載の使用。
［項４３］
前記対象が、ヒトである、上記項３４～４２のいずれか１項に記載の使用。
［項４４］
対象の寿命、年齢関連の症状、及び／または年齢関連の状態を修正する１つ以上の微生物株の能力を特徴付ける方法であって、
（ａ）哺乳動物微生物叢の複数の微生物株を複数のＣ．ｅｌｅｇａｎｓ培養物に添加することであって、異なる微生物株を各Ｃ．ｅｌｅｇａｎｓ培養物に添加し、各培養物が、同じＣ．ｅｌｅｇａｎｓ株のＣ．ｅｌｅｇａｎｓ動物を含む、前記添加することと、
（ｂ）前記複数の微生物株の各微生物株が、各培養物の前記Ｃ．ｅｌｅｇａｎｓ動物の１つ以上のパラメータに影響を及ぼすかどうかを決定することであって、前記１つ以上のパラメータが、老化、年齢関連の症状、及び／または年齢関連の状態に関連する、前記決定することと、を含む、前記方法。
［項４５］
対象の寿命、年齢関連の症状、及び／または年齢関連の状態を修正する１つ以上の１つ以上の微生物株の能力を特徴付けるための、Ｃ．ｅｌｅｇａｎｓ動物の、使用。
［項４６］
少なくとも１つの細菌株またはその抽出物もしくはその成分、及び前記賦形剤を組み合わせることを含む、上記項１～１８のいずれか１項に記載の組成物の作製方法。
本発明の実施形態は、その詳細な説明と併せて説明されてきたが、前述の説明は、添付の特許請求の範囲によって定義される本発明の範囲を説明することを意図し、限定しないことを理解されたい。その他の側面、利点、及び変更は、以下の特許請求の範囲内にある。
Embodiments of the invention are further described in the following sections:
[Section 1]
(a) at least one bacterial strain or an extract or component thereof, wherein the at least one bacterial strain is a member of the genus Gluconobacter, genus Acetobacter, genus Gluconoacaetobacter, genus Acidomonas, genus Ameyamaea, genus Asaia, genus Granulibacter, Ko genus zakia , the genus Neoasaia, the genus Neokomagataea, the genus Saccharibacter, the genus Swaminathania, the genus Tanticharoenia, or a combination thereof;
(b) an excipient.
[Section 2]
2. The composition of paragraph 1, wherein the at least one bacterial strain comprises Gluconacetobacter hansenii, Gluconobacter oxydans, Acetobacter aceti, or a combination thereof.
[Section 3]
3. The composition according to item 1 or 2, wherein the at least one bacterial strain comprises Gluconacetobacter hansenii.
[Section 4]
The at least one bacterial strain or extract or component thereof is C. C. elegans, including C. elegans animals. When administered to C. elegans cultures, the C. elegans culture. The C. elegans culture. The average lifespan of C. elegans animals is the same as that of an equivalent C. elegans animal without administration of said at least one bacterial strain or extract or component thereof. C. elegans culture. Composition according to any one of the above clauses 1 to 3, characterized in that it is prolonged by at least 20% compared to that of P. elegans animals.
[Section 5]
The at least one bacterial strain or extract or component thereof is C. C. elegans, including C. elegans animals. When administered to C. elegans cultures, the C. elegans culture. The C. elegans culture. The average pharyngeal pumping activity of C. elegans animals was greater than that of an equivalent C. elegans animal without administration of said at least one bacterial strain or extract or component thereof. C. elegans culture. Composition according to any one of the above clauses 1 to 4, characterized in that it is increased by at least 20% compared to that of P. elegans animals.
[Section 6]
The at least one bacterial strain or extract or component thereof is C. C. elegans, including C. elegans animals. When administered to C. elegans cultures, the C. elegans culture. The C. elegans culture. The average locomotor speed of C. elegans animals was higher than that of an equivalent C. elegans animal without administration of said at least one bacterial strain or extract or component thereof. C. elegans culture. Composition according to any one of the above clauses 1 to 5, characterized in that it is increased by at least 20% compared to that of P. elegans animals.
[Section 7]
The at least one bacterial strain or extract or component thereof is C. C. elegans, including C. elegans animals. When administered to C. elegans cultures, the C. elegans culture. The C. elegans culture. The reproductive performance of C. elegans animals is determined by the same level of C. elegans without administration of said at least one bacterial strain or extracts or components thereof. C. elegans culture. Composition according to any one of the above clauses 1 to 6, characterized in that the composition is reduced by at least 20% compared to that of P. elegans animals.
[Section 8]
The at least one bacterial strain or extract or component thereof is C. C. elegans, including C. elegans animals. When the C. elegans culture is exposed to ultraviolet radiation, said at least one bacterial strain or extract or component thereof has been administered. The C. elegans culture. The average survival time of C. elegans animals is longer than that of equivalent C. elegans animals without administration of said at least one bacterial strain or extract or component thereof. C. elegans culture. Composition according to any one of the above clauses 1 to 7, characterized in that it is increased by at least 20% compared to that of P. elegans animals.
[Section 9]
The at least one bacterial strain or extract or component thereof is C. C. elegans, including C. elegans animals. When the C. elegans culture is exposed to high temperatures, the at least one bacterial strain or extract or component thereof has been administered. C. elegans culture. The average survival time of C. elegans animals is longer than that of equivalent C. elegans animals without administration of said at least one bacterial strain or extract or component thereof. C. elegans culture. Composition according to any one of the above clauses 1 to 8, characterized in that it is increased by at least 20% compared to that of P. elegans animals.
[Section 10]
10. The composition according to item 9 above, wherein the high temperature is at least 37°C.
[Section 11]
The at least one bacterial strain or extract or component thereof is C. C. elegans, including C. elegans animals. When administered to C. elegans cultures, the C. elegans culture. The C. elegans culture. The average amount of intestinal fat observed in C. elegan animals is lower than that observed in C. elegan animals without administration of said at least one bacterial strain or extract or component thereof. C. elegans culture. 11. Composition according to any one of the above clauses 1 to 10, characterized in that the composition is reduced by at least 20% compared to that of P. elegans animals.
[Section 12]
Said C. elegans animals are infected with adult C. elegans animals. The composition according to any one of items 4 to 11 above, which is a P. elegans animal.
[Section 13]
Said C. 13. The composition according to any one of paragraphs 4 to 12 above, wherein the P. elegans animal is at least 5 days old.
[Section 14]
14. The composition according to any one of items 1 to 13 above, wherein the composition is formulated for oral administration.
[Section 15]
The composition according to any one of items 1 to 14 above, wherein the composition is a food, a beverage, a feed composition, or a nutritional supplement.
[Section 16]
16. The composition according to any one of items 1 to 15 above, wherein the composition is a liquid, syrup, tablet, troche, gummy, capsule, powder, gel, or film.
[Section 17]
The composition according to any one of items 1 to 16 above, wherein the composition is a pharmaceutical composition.
[Section 18]
The composition according to any one of items 1 to 17 above, wherein the composition is an enteric-coated formulation.
[Section 19]
A method comprising administering to a subject the composition according to any one of items 1 to 18 above.
[Section 20]
20. The method according to item 19, wherein the method is a method of extending the lifespan of a subject.
[Section 21]
21. The method of claim 20, wherein the lifespan of the subject is increased by at least 20% compared to that of an equivalent subject without administration of the composition.
[Section 22]
20. The method of clause 19, wherein the method is a method of reducing or delaying the onset of at least one age-related symptom or condition in a subject.
[Section 23]
23. The method of clause 22, wherein the at least one age-related symptom or condition is reduced or delayed in the subject by at least 20% as compared to an equivalent subject without administration of the composition.
[Section 24]
24. The method of paragraph 22 or 23, wherein said at least one age-related symptom or condition is or comprises a decline in muscle and/or neuromuscular function of said subject.
[Section 25]
25. The method of any one of paragraphs 22 to 24 above, wherein said at least one age-related symptom or condition is or comprises dysregulation of lipid metabolism.
[Section 26]
26. The method according to any one of paragraphs 19 to 25 above, wherein the subject is at least 30 years old.
[Section 27]
27. The method according to any one of items 19 to 26 above, wherein the subject is an elderly subject.
[Section 28]
28. The method according to any one of items 19 to 27 above, wherein the subject is a mammal.
[Section 29]
29. The method according to any one of items 19 to 28 above, wherein the subject is a human.
[Section 30]
30. The method according to any one of items 19 to 29 above, comprising administering an amount of microorganisms sufficient to colonize the microbial flora of the subject.
[Section 31]
Use of at least one bacterial strain or extract or component thereof for extending the lifespan of a subject, wherein the at least one bacterial strain is a member of the genus Gluconobacter, the genus Acetobacter, the genus Gluconoacaetobacter, the genus Acidomonas, the genus Ameyamaea, the genus Asaia. , Granulibacter, Kozakia, Neoasaia, Neokomagataea, Saccharibacter, Swaminathania, Tanticharoenia, or combinations thereof.
[Section 32]
32. The use according to clause 31, wherein the at least one bacterial strain comprises Gluconacetobacter hansenii, Gluconobacter oxydans, Acetobacter aceti, or a combination thereof.
[Section 33]
The use according to paragraph 31 or 32 above, wherein the at least one bacterial strain comprises Gluconacetobacter hansenii.
[Section 34]
Use of at least one bacterial strain or extract or component thereof to reduce or delay the onset of at least one age-related symptom or condition in a subject, wherein said at least one bacterial strain is a member of the genus Gluconobacter, genus Acetobacter, Gluconoacaetobacter Genus, Acidomonas, Ameyamaea, Asaia, Granulibacter, Kozakia, Neoasaia, Neokomagataea, Saccharibacter, Swaminathania, Tantich Said use comprising the genus aroenia, or a combination thereof.
[Section 35]
35. The use according to paragraph 34, wherein the at least one bacterial strain comprises Gluconacetobacter hansenii, Gluconobacter oxydans, Acetobacter aceti, or a combination thereof.
[Section 36]
36. The use according to paragraph 34 or 35 above, wherein the at least one bacterial strain comprises Gluconacetobacter hansenii.
[Section 37]
35. The use according to clause 34, wherein said at least one age-related symptom or condition is reduced or delayed in said subject by at least 20% compared to that of an equivalent subject without administration of the composition.
[Section 38]
Use according to any one of the above clauses 34 to 37, wherein said at least one age-related symptom or condition is or comprises a decline in muscle and/or neuromuscular function of said subject.
[Section 39]
The use according to any one of paragraphs 34 to 38 above, wherein said at least one age-related symptom or condition is or comprises dysregulation of lipid metabolism.
[Section 40]
The use according to any one of clauses 34 to 39 above, wherein the subject is at least 30 years old.
[Section 41]
The use according to any one of the above items 34 to 40, wherein the subject is an elderly subject.
[Section 42]
The use according to any one of the above items 34 to 41, wherein the subject is a mammal.
[Section 43]
The use according to any one of the above items 34 to 42, wherein the subject is a human.
[Section 44]
A method of characterizing the ability of one or more microbial strains to modify lifespan, age-related symptoms, and/or age-related conditions in a subject, the method comprising:
(a) Multiple microbial strains of the mammalian microbiome are combined with multiple C. elegans culture, by adding different microbial strains to each C. elegans culture. C. elegans cultures, each culture containing the same C. elegans culture. C. elegans strain. elegans animal;
(b) Each of the microbial strains of the plurality of microbial strains has the C. elegans animal, wherein the one or more parameters are associated with aging, an age-related symptom, and/or an age-related condition. The method comprises:
[Section 45]
C. for characterizing the ability of one or more microbial strains to modify lifespan, age-related symptoms, and/or age-related conditions in a subject. elegans animals, use.
[Section 46]
19. A method for making a composition according to any one of paragraphs 1 to 18 above, comprising combining at least one bacterial strain or an extract thereof or a component thereof and the excipient.
While embodiments of the invention have been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the appended claims. I want you to understand. Other aspects, advantages, and modifications are within the scope of the following claims.
Claims (46)
（ｂ）賦形剤と、を含む、組成物。 (a) at least one bacterial strain or an extract or component thereof, wherein the at least one bacterial strain is a member of the genus Gluconobacter, genus Acetobacter, genus Gluconoacaetobacter, genus Acidomonas, genus Ameyamaea, genus Asaia, genus Granulibacter, Ko genus zakia , the genus Neoasaia, the genus Neokomagataea, the genus Saccharibacter, the genus Swaminathania, the genus Tanticharoenia, or a combination thereof;
(b) an excipient.
（ａ）哺乳動物微生物叢の複数の微生物株を複数のＣ．ｅｌｅｇａｎｓ培養物に添加することであって、異なる微生物株を各Ｃ．ｅｌｅｇａｎｓ培養物に添加し、各培養物が、同じＣ．ｅｌｅｇａｎｓ株のＣ．ｅｌｅｇａｎｓ動物を含む、前記添加することと、
（ｂ）前記複数の微生物株の各微生物株が、各培養物の前記Ｃ．ｅｌｅｇａｎｓ動物の１つ以上のパラメータに影響を及ぼすかどうかを決定することであって、前記１つ以上のパラメータが、老化、年齢関連の症状、及び／または年齢関連の状態に関連する、前記決定することと、を含む、前記方法。 A method of characterizing the ability of one or more microbial strains to modify lifespan, age-related symptoms, and/or age-related conditions in a subject, the method comprising:
(a) Multiple microbial strains of the mammalian microbiome are combined with multiple C. elegans culture, by adding different microbial strains to each C. elegans culture. C. elegans cultures, each culture containing the same C. elegans culture. C. elegans strain. elegans animal;
(b) Each of the microbial strains of the plurality of microbial strains is selected from the C. elegans animal, wherein the one or more parameters are associated with aging, an age-related symptom, and/or an age-related condition. The method comprises:
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962909186P | 2019-10-01 | 2019-10-01 | |
| US62/909,186 | 2019-10-01 | ||
| PCT/US2020/052251 WO2021067100A1 (en) | 2019-10-01 | 2020-09-23 | Compositions and methods for extending lifespan |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022551584A JP2022551584A (en) | 2022-12-12 |
| JPWO2021067100A5 true JPWO2021067100A5 (en) | 2023-09-28 |
Family
ID=75337328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520294A Pending JP2022551584A (en) | 2019-10-01 | 2020-09-23 | Compositions and methods for extending life |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220330597A1 (en) |
| EP (1) | EP4037697A4 (en) |
| JP (1) | JP2022551584A (en) |
| KR (1) | KR20220073796A (en) |
| CN (1) | CN114555102A (en) |
| AU (1) | AU2020359357A1 (en) |
| CA (1) | CA3153779A1 (en) |
| IL (1) | IL291798A (en) |
| WO (1) | WO2021067100A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114365845B (en) * | 2022-02-18 | 2023-03-28 | 吉林大学 | Plant fermentation composition and preparation method and application thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008214215A (en) * | 2007-03-01 | 2008-09-18 | Mitsukan Group Honsha:Kk | Composition having apoptosis induction ability |
| US20160051596A1 (en) * | 2014-08-21 | 2016-02-25 | Food Industry Research And Development Institute | Novel acetobacter and gluconacetobacter strains and their metabolites for use in inhibiting xanthine oxidase |
| US10722543B2 (en) * | 2016-01-28 | 2020-07-28 | Oxyrase, Inc. | Methods for inhibiting tumor growth using anaerobe microorganisms |
| JP2018131416A (en) * | 2017-02-16 | 2018-08-23 | 国立大学法人 鹿児島大学 | Immunopotentiators and methods of making the same |
| WO2019043951A1 (en) * | 2017-09-04 | 2019-03-07 | キユーピー株式会社 | Food composition containing cells of acetic acid bacterium, and method for producing same |
| WO2019147652A1 (en) * | 2018-01-23 | 2019-08-01 | The General Hospital Corporation | Compositions and methods for improving mitochondrial function |
| US11284609B2 (en) * | 2019-09-12 | 2022-03-29 | MarvelBiome, Inc. | Compositions and methods for characterizing a microbiome |
-
2020
- 2020-09-23 CA CA3153779A patent/CA3153779A1/en active Pending
- 2020-09-23 AU AU2020359357A patent/AU2020359357A1/en active Pending
- 2020-09-23 US US17/765,820 patent/US20220330597A1/en active Pending
- 2020-09-23 JP JP2022520294A patent/JP2022551584A/en active Pending
- 2020-09-23 WO PCT/US2020/052251 patent/WO2021067100A1/en active Application Filing
- 2020-09-23 KR KR1020227014286A patent/KR20220073796A/en unknown
- 2020-09-23 CN CN202080069037.3A patent/CN114555102A/en active Pending
- 2020-09-23 IL IL291798A patent/IL291798A/en unknown
- 2020-09-23 EP EP20872800.6A patent/EP4037697A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11872255B2 (en) | Methods and compositions of preventing and treating dental caries | |
| JP4455333B2 (en) | Probiotic bacteria: Lactobacillus fermentum | |
| CN109419814B (en) | Application of paradisella gordonii to inhibition of fatty liver disease | |
| EP3560506A1 (en) | Pharmaceutical composition comprising indigo pulverata levis extract or fraction thereof as effective ingredient for preventing or treating inflammatory bowel disease | |
| CN106994134B (en) | Application of intestinal probiotics in prevention and/or treatment of diabetes and related diseases thereof | |
| Hoseinifar et al. | Dietary apple peel-derived pectin improved growth performance, antioxidant enzymes and immune response in common carp, Cyprinus carpio (Linnaeus, 1758) | |
| WO2018090983A9 (en) | Saponin compound for improving intestinal microflora, preparation method and use thereof | |
| CN113925923B (en) | Anti-acne and whitening compound probiotic composition and preparation method thereof | |
| JP5945092B2 (en) | Neutral fat reducing agent | |
| JP2020516699A (en) | Tumor Chemotherapy Microbial Agents to Prevent Enterotoxicity | |
| CN109419816B (en) | Application of bacteroides cellulolyticus in preventing and/or treating heart diseases | |
| NO331751B1 (en) | Use of dietary fiber or a mixture of dietary fiber for the preparation of a composition for oral administration for the treatment of systemic infections in fish. | |
| JP2022508125A (en) | Use of Lactobacillus plantarum TWK10 in the manufacture of probiotic compositions for post-exercise inflammation or body fat reduction | |
| JP5843169B2 (en) | Fructose absorption inhibitor | |
| JP2018532380A (en) | Enterobacteriaceae butyric acid intestini and uses thereof | |
| WO2019109348A1 (en) | Use of butyribacter intestini in preventing and/or treating inflammation-related diseases | |
| JPWO2021067100A5 (en) | ||
| WO1998035664A1 (en) | Athletic endurance increasing agent in food | |
| Asok et al. | Probiotics and periodontal disease | |
| CN110869035A (en) | Application of xenobacter saxifragi in preparation of composition for preventing and/or treating lipid metabolism-related diseases | |
| KR102158598B1 (en) | Composition for preventing or treating behcet's diseases or herpes simplex virus infection containing lactobacillus animalis | |
| JP2018118915A (en) | Non-alcoholic liver injury inhibitor | |
| JP2014005225A (en) | Agent for suppressing appetite improvement and body weight gain | |
| JP2022552759A (en) | Composition for prevention or treatment of obesity or obesity-induced metabolic syndrome containing Enterococcus faecalis as an active ingredient | |
| CN106974940B (en) | Application of probiotics of scleritis in treating and preventing obesity and related diseases |